Table of Contents
Historical Data, Premium Insights, Market Dynamic, Analysis and Projection, By Product, Analysis and Projection, By Application, Analysis and Projection, By End-Use, Analysis and Projection, By Regional Analysis, Competitive Landscape, Company Profiles, Market Revenue, Sale & Price Analysis
Related Topics
Bovine Respiratory Disease Treatment Market Size Blue Eye Disease Vaccines Market Size Autoimmune Disease Therapeutics Market Size Freelance Platforms Market SizeGlobal Brain Disease Modalities and Software Market Size to Exceed USD 23.22 Billion by 2033
According to a research report published by Spherical Insights & Consulting, The Global Brain Disease Modalities and Software Market Size is Expected to Grow from USD 14.15 Billion in 2023 to USD 23.22 Billion by 2033, at a CAGR of 5.08% during the forecast period 2023-2033.
Browse 210 market data Tables and 45 Figures spread through 190 Pages and in-depth TOC on the Global Brain Disease Modalities and Software Market Size, Share, and COVID-19 Impact Analysis, By Type (Imaging Devices [Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron Emission Tomography (PET), Single-Photon Emission Computed Tomography (SPECT), and Electroencephalography (EEG)] and Software [Detecting brain abnormalities, Measuring brain volume, Tracking disease progression, and Aiding in surgical planning]), By Patient Type (Adults, Pediatrics, and Infants), By Application (Alzheimer's Disease, Dementia, Stroke, Multiple sclerosis, Parkinson's disease, Brain Tumors Epilepsy, and Traumatic Brain Injury (TBI)), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033.
The brain disease modalities and software industry describes the international market centered on diagnostic, therapeutic, and research modalities employed in detecting, analyzing, and treating brain disease and disorder. It consists of imaging modalities (MRI, CT, PET, EEG), artificial intelligence-based diagnostic software, neuroinformatics applications, and brain mapping tools employed in disorders like Alzheimer's, Parkinson's, epilepsy, stroke, and brain tumors. Furthermore, major driving forces for the global brain disease modalities and software market are growing incidences of neurological disorders, innovation in brain imaging technologies, greater acceptance of AI-based diagnostic software, and enhanced healthcare investments. Further, the increasing geriatric population, better early diagnosis potentials, and government incentives for neurological research also drive the growth in the market during the forecast years. However, the high costs of imaging systems, limited accessibility in low-income regions, stringent regulatory approvals, data privacy concerns, and a shortage of skilled professionals are key restraints for the growth of the market.
The imaging devices segment accounted for the largest share in 2023 and is anticipated to grow at a significant CAGR during the forecast period.
On the basis of the type, the global brain disease modalities and software market is divided into imaging devices and software. The imaging devices are divided into magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), single-photon emission computed tomography (SPECT), and electroencephalography (EEG). The software is divided into detecting brain abnormalities, measuring brain volume, tracking disease progression, and aiding in surgical planning. Among these, the imaging devices segment accounted for the largest share in 2023 and is anticipated to grow at a significant CAGR during the forecast period. The segmental growth is attributed to the high demand for advanced brain imaging technologies like MRI, CT, and PET scans for accurate diagnosis of neurological disorders. Technological advancements, increasing prevalence of brain diseases, and rising healthcare investments further drive its significant CAGR during the forecast period.
The adult segment accounted for the largest share in 2023 and is anticipated to grow at a remarkable CAGR during the forecast period.
On the basis of the patient type, the global brain disease modalities and software market is divided into adult, pediatrics, and infants. Among these, the adult segment accounted for the largest share in 2023 and is anticipated to grow at a remarkable CAGR during the forecast period. The segmental growth is attributed to the high prevalence of brain diseases like stroke, Alzheimer's, and Parkinson's among adults. Aging populations, increasing awareness, advancements in diagnostic technologies, and rising healthcare investments further drive its remarkable CAGR, ensuring sustained market growth throughout the forecast period.
The stroke segment accounted for the greatest share in 2023 and is anticipated to grow at a substantial CAGR over the forecast period.
On the basis of the application, the global brain disease modalities and software market is divided into Alzheimer's disease, dementia, stroke, multiple sclerosis, Parkinson's disease, brain tumors epilepsy, and traumatic brain injury (TBI). Among these, the stroke segment accounted for the greatest share in 2023 and is anticipated to grow at a substantial CAGR over the forecast period. The segmental growth is attributed to its high global prevalence, rising aging population, and increasing risk factors like hypertension and diabetes. Advancements in imaging technologies, growing awareness of early diagnosis, and government initiatives for stroke management further drive its substantial CAGR, ensuring strong market growth over the forecast period.
North America is projected to hold the largest share of the global brain disease modalities and software market over the forecast period.
North America is projected to hold the largest share of the global brain disease modalities and software market over the forecast period. The regional growth is attributed to the high prevalence of neurological disorders, advanced healthcare infrastructure, strong government funding for research, and rapid adoption of cutting-edge imaging technologies. Additionally, the presence of key market players and increasing awareness of early diagnosis further drive market growth in the region.
Asia Pacific is expected to grow at the fastest CAGR growth of the global brain disease modalities and software market during the forecast period. The segmental growth is attributed to the rising neurological disease prevalence, expanding healthcare infrastructure, and increasing investments in medical imaging technologies. Additionally, growing awareness, government initiatives for brain health, and an aging population further drive rapid market expansion throughout the forecast period.
Company Profiling
Major vendors in the global brain disease modalities and software market are Quantib, Brainomix, General Electric Company, Imaging Biometrics, LLC, United Imaging Healthcare Co. Ltd., Siemens Healthineers AG, Koninklijke Philips N.V., Canon Inc., Vuno Co. Ltd., Aspect Imaging, IXICO, Fujifilm Holdings Corporation, and others.
Key Target Audience
Recent Development
Market Segment
This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global brain disease modalities and software market based on the below-mentioned segments:
Global Brain Disease Modalities and Software Market, By Type
Global Brain Disease Modalities and Software Market, By Patient Type
Global Brain Disease Modalities and Software Market, By Application
Global Brain Disease Modalities and Software Market, By Regional
May 2025 - The Global Automotive Exit Warning System Market Size is Expected to Grow from USD 1.05 Billion in 2023 to USD 3.75 Billion by 2033, Growing at a CAGR of 13.58% during the forecast period 2023-2033.
May 2025 - The Global Chronic Kidney Disease Treatment Market Size is Expected to Grow from USD 33.20 Billion in 2023 to USD 47.99 Billion by 2033, at a CAGR of 3.75% during the forecast period 2023-2033
May 2025 - The Global Chronic Kidney Disease Market Size is Expected to Grow from USD 38.30 Billion in 2023 to USD 66.65 Billion by 2033, at a CAGR of 5.70% during the forecast period 2023-2033
We have received your message and would like to thank you for writing to us. If your inquiry is urgent, please use the telephone number listed below to talk to one of our staff members. Otherwise, we will reply by email as soon as possible.
